Paper of the Month: Tanja Kuhlmann & Luisa Klotz
- MÜNSTER, Germany – Researchers at the University of Münster's Medical Faculty have identified a potential biomarker for rapid disease progression in multiple sclerosis (MS).
- The research, led by Clotz L., Smolders J., Lehto J., Matilain M., Lüje L., Buchholz L., Albreight S., Walter C., Varghse J., and Nylund C., along with Gardberg...
- Multiple sclerosis, a chronic inflammatory disease affecting the central nervous system, manifests in various forms.
Myeloid Rim lesions Linked to Rapid Multiple Sclerosis Progression
Table of Contents
- Myeloid Rim lesions Linked to Rapid Multiple Sclerosis Progression
- Myeloid Rim Lesions and Rapid MS Progression: Your Questions Answered
- What is Multiple Sclerosis (MS)?
- What are the Different Forms of MS?
- What is the Latest Research on MS Progression?
- What is a Myeloid Rim Lesion?
- what Did the Study Find?
- Who Led the Research?
- What Methods Were Used in the Study?
- What is Spatial Transcriptomics?
- Why is This Research Important?
- What Are the Implications for MS Treatment?
- Can you Summarize the Key Findings?
- Where Can I Find the Full Study?
- What Does This Research Mean for the Future of MS Treatment?
MÜNSTER, Germany – Researchers at the University of Münster’s Medical Faculty have identified a potential biomarker for rapid disease progression in multiple sclerosis (MS). The study, highlighted as the faculty’s “Paper of the Month” for April 2025, focuses on a specific type of lesion characterized by a wide rim of myeloid cells.
Study Details
The research, led by Clotz L., Smolders J., Lehto J., Matilain M., Lüje L., Buchholz L., Albreight S., Walter C., Varghse J., and Nylund C., along with Gardberg M. of Bosch AMR and airas A., was published in Brain on April 29, 2025. The paper is titled “A new pathologic and imaging biomarker for rapid disease progression in multiple sclerosis.”
The study can be found on PubMed.
Key findings
Multiple sclerosis, a chronic inflammatory disease affecting the central nervous system, manifests in various forms. While current treatments effectively manage relapse-related symptoms, their impact on progressive forms of the disease remains limited.
This study identified a subgroup of patients exhibiting rapid disease progression through advanced imaging techniques. The researchers discovered that lesions with a wide edge of myeloid cells are characteristic of this aggressive form of MS. this finding suggests that therapies modulating the innate immune response of these cells could potentially benefit patients experiencing a faster disease course.
Implications for MS treatment
The research team analyzed a cohort of 186 MS autopsy cases, selecting donors with either slow or rapid disease progression. Through complete tissue analysis and spatial transcriptomics,they identified a distinct type of MS lesion surrounded by a wide rim of myeloid cells,exhibiting unique transcriptome patterns.
An self-reliant positron emission tomography (PET) study involving 114 participants corroborated these findings, confirming the association between lesions with a broad myeloid margin and rapid disease progression.
“These results provide important insights into the mechanisms of MS progression,” the researchers stated, “identifying lesions with a wide edge of the cell as a biomarker for a quick disease progression and could influence patient selection for future therapeutic studies on the treatment of MS.”
Underlying Mechanisms
The study offers crucial insights into the mechanisms driving MS progression. Identifying broad rim lesions as a biomarker could refine patient selection for future clinical trials focused on treating central nervous system inflammation.
Myeloid Rim Lesions and Rapid MS Progression: Your Questions Answered
This article explores a recent study that links a specific type of lesion in the brain to faster disease progression in multiple sclerosis (MS). We’ll break down the findings in a clear, easy-to-understand Q&A format.
What is Multiple Sclerosis (MS)?
MS is a chronic, inflammatory disease that affects the central nervous system (brain and spinal cord). It disrupts the normal function of the brain, spinal cord, and optic nerves. This can lead to a wide range of symptoms.
What are the Different Forms of MS?
MS can manifest in various forms, with different rates of progression and symptom presentations. Current treatments are more effective at managing relapse-related symptoms.
What is the Latest Research on MS Progression?
Researchers at the University of Münster’s Medical Faculty in Germany have identified a potential biomarker for rapid disease progression in MS. The study, published in the journal Brain on April 29, 2025, focused on a specific type of lesion.
What is a Myeloid Rim Lesion?
The study highlighted a specific type of lesion characterized by a “wide rim of myeloid cells.” These myeloid cells are a type of immune cell.
what Did the Study Find?
The study found that lesions with a wide edge of myeloid cells are associated with rapid MS progression. autopsy cases and an independent PET (positron emission tomography) study corroborated these findings.
Who Led the Research?
The study was led by Clotz L., Smolders J., Lehto J.,matilain M.,Lüje L., buchholz L., Albreight S., Walter C., Varghse J., and Nylund C.,along with Gardberg M.of Bosch AMR and Airas A.
What Methods Were Used in the Study?
The research team analyzed 186 MS autopsy cases, comparing those with slow versus rapid disease progression. They used complete tissue analysis and spatial transcriptomics to identify lesion characteristics. A subsequent PET study with 114 participants further confirmed the findings.
What is Spatial Transcriptomics?
spatial transcriptomics allows researchers to analyze the activity of genes within specific locations in a tissue sample. In this study,it helped to identify unique transcriptome patterns in the myeloid rim lesions.
Why is This Research Important?
The identification of this biomarker could significantly impact patient care by:
Improving Diagnosis: Helping to identify patients at risk for rapid disease progression.
Personalized Treatment: Influencing patient selection for clinical trials.
* Developing Targeted Therapies: Providing insights into mechanisms of MS progression and opportunities for therapeutic intervention.
What Are the Implications for MS Treatment?
The researchers believe that therapies that modulate the innate immune response of myeloid cells could perhaps benefit patients experiencing a faster disease course. This research could influence future therapeutic studies.
Can you Summarize the Key Findings?
Sure, here is a table summarizing the key findings:
| Finding | Description | Importance |
| :———————————— | :——————————————————————————————————————————————— | :————————————————————————————————————————————————————— |
| Myeloid Rim Lesions | Specific type of lesion with a wide rim of myeloid cells. | Potential biomarker for rapid MS progression. |
| Association with Rapid Progression | Lesions with wide myeloid rims are linked to faster disease progression. | helps identify patients at risk. |
| Therapeutic Potential | Therapies modulating the innate immune response of myeloid cells could be beneficial. | Could refine patient selection for clinical trials and assist in developing targeted treatments, potentially improving outcomes for rapid-progressing MS. |
| Study Methods | 186 MS autopsy cases were analyzed; supported by a PET study of 114 participants | Confirms the association between the biomarker in question to rapid MS progression.|
Where Can I Find the Full Study?
The study, titled “A new pathologic and imaging biomarker for rapid disease progression in multiple sclerosis,” is available on PubMed. You can find it at this link: PubMed.
What Does This Research Mean for the Future of MS Treatment?
This research offers a crucial step toward understanding the mechanisms driving MS progression. Identifying broad rim lesions as a biomarker could refine patient selection for future clinical trials. It may enable the progress of more effective and personalized treatments for those affected by this disease.